We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > eFFECTOR

News List

eFFECTOR and QBI to study anti-viral agent for Covid-19 treatment pharmaceutical-technology
May 06, 2021
eFFECTOR Therapeutics and Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), have announced a $5m cooperative agreement for a planned Phase Ib study of zotatifin (eFT226), an anti-viral agent for Covid-19 ...
Pfizer signs oncology agreement with STR-focused eFFECTOR pharmaceutical-technology
January 14, 2020
San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field. The collaboration focuses on the development of small molecule inhibitors of eukaryotic initiation factor 4E (elF4E) ...
eFFECTOR Therapeutics completes $38.6 million Series C financing biospectrumasia
August 11, 2017
Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments.